It's become increasingly clear that the gut microbiome can affect human health, including mental health. Which bacterial ...
Johnson & Johnson (NYSE: JNJ) announced today the U.S. Food and Drug Administration (FDA) approval of a supplemental New Drug Application (sNDA) for SPRAVATO® (esketamine) CIII nasal spray, making ...
Glamour on MSN5d
The Winter Blues Are a Real Thing—Here’s How to Manage ThemAccording to Dr. Alexandra Stratyner, Ph.D., co-founder of Stratyner & Associates Psychology, the winter are blues are very ...
Chief Executive Officer of Msheireb Properties, Eng. Ali Al Kuwari, highlighted the company's remarkable achievements in 2024 ...
For people with anxiety and depression, these conditions can feel like two sides of the same coin. Researchers are exploring ...
A. Antidepressants are approved for use by the Food and Drug Administration in major depressive disorder, some of them in ...
A Missouri Republican last week announced his intent to introduce a bill to legalize and regulate psilocybin therapy for ...
It's become increasingly clear that the gut microbiome can affect human health, including mental health. Which bacterial species influence the ...
Spravato is now the first-ever standalone therapy for treatment-resistant depression, and is on its way to becoming a blockbuster product.
So it ended, very cordially and mutually, but I needed to do that for myself ... The coworker and I have remained cordial and understand each other in a professional way. However, I received ...
Johnson & Johnson has agreed to acquire Intra-Cellular Therapies for approximately $14.6 billion, in the largest biopharma merger-and-acquisition (M&A) deal announced in two years.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback